Notice2023-01371
Notice Pursuant to the National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc.
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 25, 2023
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 16 (Wednesday, January 25, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 16 (Wednesday, January 25, 2023)]
[Notices]
[Page 4850]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-01371]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Subcutaneous Drug Development & Delivery
Consortium, Inc.
Notice is hereby given that, on December 21, 2022, pursuant to
Section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug
Development & Delivery Consortium, Inc. (``Subcutaneous Drug
Development & Delivery Consortium, Inc.'') has filed written
notifications simultaneously with the Attorney General and the Federal
Trade Commission disclosing changes in its membership. The
notifications were filed for the purpose of extending the Act's
provisions limiting the recovery of antitrust plaintiffs to actual
damages under specified circumstances. Specifically, Biogen Inc.,
Cambridge, MA; C.H. Boehringer Sohn AG & Co. KG, Ridgefield, CT;
Kal[eacute]o, Inc., Richmond, VA; KORU Medical Systems, Mahwah, NJ;
NEMERA La Verpilliere SAS, La Verpilliere, FRANCE; and Comera Life
Sciences, Woburn, MA, have been added as parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and Subcutaneous Drug Development &
Delivery Consortium, Inc. intends to file additional written
notifications disclosing all changes in membership.
On October 26, 2020, Subcutaneous Drug Development & Delivery
Consortium, Inc. filed its original notification pursuant to Section
6(a) of the Act. The Department of Justice published a notice in the
Federal Register pursuant to Section 6(b) of the Act on December 3,
2020 (85 FR 78148).
The last notification was filed with the Department on April 25,
2022. A notice was published in the Federal Register pursuant to
Section 6(b) of the Act on May 13, 2022 (87 FR 29381).
Suzanne Morris,
Deputy Director of Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2023-01371 Filed 1-24-23; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on January 25, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.